ClinicalTrials.gg
CompletedNCT07950709NARCO-DENTUpdated Nov 20, 2026

NARCO Score and ASA Physical Status for Predicting Airway Spasm in Children Having Dental Treatment Under General Anaesthesia

An observational study in Bronchial Spasm, Anesthesia and Dental Caries, sponsored by Ankara University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 1 Year to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Ankara University · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,484
Ages
1 Year to 16 Years
Sex
All
01

Study summary

A sudden spasm of the airway (laryngospasm or bronchospasm) is one of the most common serious problems when children have general anaesthesia. Before surgery, anaesthesiologists use scoring systems to estimate a child's risk. In this study, the investigators reviewed the anaesthesia records of children aged 1 to 16 years who had dental treatment under general anaesthesia at Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital (Ankara, Türkiye) between January 2022 and December 2023. The study tested whether two such systems, the NARCO score and the ASA physical status classification, could identify the children who went on to have an airway spasm during anaesthesia or in the recovery room. No treatment was given or changed for this study; all information came from existing records.

Read the detailed description

Design: single-centre retrospective cohort study of all dental procedures performed under general anaesthesia in children aged 1-16 years at Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital between January 2022 and December 2023 (1,548 procedures: 1,468 identified children and 16 records without a patient identifier). Predictors: ASA physical status as recorded at the preoperative visit, and the NARCO score (neurological, airway, respiratory, cardiovascular and other domains, each 0-2, plus a surgical severity subscore). NARCO domain scores were derived from the documented preoperative comorbidity record and structured preoperative variables with a pre-defined keyword-to-domain algorithm. Information recorded after induction, including the anaesthetic complication field, was not used for scoring. Outcome: perioperative airway event, defined as airway spasm (laryngospasm or bronchospasm) or oxygen desaturation requiring intensive care admission, documented between induction and discharge from the post-anaesthesia care unit. Analysis: discrimination (area under the ROC curve, DeLong paired comparison), calibration (calibration slope, calibration-in-the-large, scaled Brier score), bootstrap internal validation and decision curve analysis; multivariable logistic regression adjusted for ASA physical status, age and sex; sensitivity analyses accounting for clustering within children, restricted to the first procedure per child, and with multiple imputation. Validation substudy: two anaesthesiologists blinded to the outcome independently re-scored an outcome-stratified random sample of 300 procedures (all procedures with an event and a random sample of those without); disagreements were resolved by consensus, and 30 records were re-scored after 14-15 days to assess test-retest reliability. Reporting follows STROBE and TRIPOD+AI. This study was registered retrospectively, after data collection and analysis had been completed.

02

Conditions studied

  • Bronchial Spasm
  • Anesthesia
  • Dental Caries
  • Laryngismus

Keywords

  • NARCO score
  • ASA physical status
  • paediatric anaesthesia
  • laryngospasm
  • risk prediction
03

In context

Bronchial Spasm

45 studies on the registry are indexed under Bronchial Spasm; 4 are open to participants now.

This study's enrollment of 1,484 is above the median of 150 across 15 observational studies indexed under Bronchial Spasm.

Browse Bronchial Spasm studies →

Lead sponsor

Ankara University is the lead sponsor of 323 studies on the registry; 65 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive children aged 1-16 years who had dental treatment under general anaesthesia at Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital, a tertiary paediatric hospital in Ankara, Türkiye.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 to 16 years
  • Dental treatment under general anaesthesia at Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital between January 2022 and December 2023

Exclusion criteria

Exclusion Criteria:

  • None (all eligible records in the study period were included)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,484 participants (actual)
Patient registry
No

Groups and cohorts

  • Children having dental treatment under general anaesthesia

    Children aged 1-16 years who had dental treatment under general anaesthesia at Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital between January 2022 and December 2023. No intervention was assigned by the investigators.

06

What researchers measure

Primary outcomes

  1. Perioperative airway event

    Number of procedures with airway spasm (laryngospasm or bronchospasm) or oxygen desaturation requiring admission to intensive care, documented in the anaesthetic complication field between induction of anaesthesia and discharge from the post-anaesthesia care unit.

    Time frame: Perioperative

  2. Discrimination of the NARCO score for perioperative airway events.

    Area under the receiver operating characteristic curve (range 0.5 to 1; higher values indicate better discrimination) of the NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome).

    Time frame: Perioperative

Secondary outcomes

  1. Discrimination of ASA physical status and paired comparison with the NARCO score.

    Area under the ROC curve of the American Society of Anesthesiologists Physical Status (ASA-PS) classification (range class I to VI; higher classes indicate more severe systemic disease, i.e. a worse outcome), and paired difference from the NARCO score (DeLong test).

    Time frame: Perioperative

  2. Association between NARCO score and perioperative airway events.

    Odds ratio per point of the NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome), adjusted for ASA physical status, age and sex.

    Time frame: Perioperative

  3. Diagnostic accuracy of NARCO thresholds.

    Sensitivity, specificity, predictive values and likelihood ratios at total scores of ≥1, ≥2 and ≥3 on the NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome).

    Time frame: Perioperative

  4. Calibration and internal validity.

    Calibration slope, calibration-in-the-large, scaled Brier score and optimism-corrected c-statistic (bootstrap) of a logistic model including the NARCO score, ASA physical status, age and sex.

    Time frame: Perioperative

  5. Clinical usefulness

    Net benefit of classifying children with a NARCO score ≥1 as high risk, on decision curve analysis at threshold probabilities of 1% to 25%.

    Time frame: Perioperative

Other outcomes

  1. Inter-rater reliability of the clinician-assigned NARCO score.

    Intraclass correlation coefficient ICC(2,1) for the total NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome), and Cohen's kappa and Gwet's AC1 for each domain, between two blinded anaesthesiologists in an outcome-stratified sample of 300 procedures.

    Time frame: Baseline

  2. Discrimination of the consensus clinician-assigned NARCO score.

    Area under the ROC curve (range 0.5 to 1; higher values indicate better discrimination) of the consensus NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome) in the re-scored sample.

    Time frame: Perioperative

  3. Test-retest reliability of the clinician-assigned NARCO score.

    ICC(2,1) for the total NARCO score (Neurological, Airway, Respiratory, Cardiovascular, Other; each domain scored 0-2, total range 0-10; higher scores indicate greater perioperative risk, i.e. a worse outcome) in 30 records scored twice by each assessor, 14-15 days apart.

    Time frame: Baseline and 2 weeks

07

Study locations

1 site
  • Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital
    Ankara, 06080, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared, to protect patient confidentiality in accordance with the Turkish Personal Data Protection Law (No. 6698). The statistical analysis plan and analysis code are available from the principal investigator on request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Dec 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 20, 2026
StartActual
Jan 1, 2022
Primary completionActual
Dec 31, 2023
CompletionActual
Oct 24, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950709
Lead sponsor
Ankara University
Collaborators
Dr. Sami Ulus Children's Hospital
Responsible party
Cagil Vural (Associate Professor, Ankara University) — Principal investigator
First posted
Nov 20, 2026
Start date
Jan 1, 2022
Primary completion
Dec 31, 2023
Completion
Oct 24, 2026
Last update
Nov 20, 2026

Study contacts

ÇAĞIL VURAL, MD
principal investigator · Ankara University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion